PLUR vs. BCLI, ACHL, SRZN, SABS, ESLA, INKT, QNCX, CYTH, CASI, and CRTX
Should you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Brainstorm Cell Therapeutics (BCLI), Achilles Therapeutics (ACHL), Surrozen (SRZN), SAB Biotherapeutics (SABS), Estrella Immunopharma (ESLA), MiNK Therapeutics (INKT), Quince Therapeutics (QNCX), Cyclo Therapeutics (CYTH), CASI Pharmaceuticals (CASI), and Cortexyme (CRTX). These companies are all part of the "medical" sector.
Pluri (NASDAQ:PLUR) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, community ranking, media sentiment and profitability.
Pluri has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.
Brainstorm Cell Therapeutics received 290 more outperform votes than Pluri when rated by MarketBeat users.
Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -6,339.59%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Pluri's return on equity.
In the previous week, Brainstorm Cell Therapeutics had 8 more articles in the media than Pluri. MarketBeat recorded 9 mentions for Brainstorm Cell Therapeutics and 1 mentions for Pluri. Brainstorm Cell Therapeutics' average media sentiment score of 0.67 beat Pluri's score of -0.60 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the news media.
Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Pluri. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.
16.6% of Pluri shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 10.2% of Pluri shares are owned by company insiders. Comparatively, 5.5% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Brainstorm Cell Therapeutics beats Pluri on 7 of the 13 factors compared between the two stocks.
Get Pluri News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
